Press Releases

Date	Title
12/12/12	Sarepta Therapeutics Announces Proposed Public Offering of Common Stock
12/7/12	Sarepta Therapeutics Announces a Continued Benefit on Walking Test Through 62 Weeks in Phase IIb Open-Label Extension Study of Eteplirsen in Duchenne Muscular Dystrophy
11/27/12	Sarepta Therapeutics to Present Company Overview at the Deutsche Bank 2012 dbAccess BioFEST Conference
11/26/12	Sarepta Therapeutics Enters Into Collaboration for the Development of Additional Exon-Skipping Product for Duchenne Muscular Dystrophy
11/20/12	Sarepta Therapeutics to Present Company Overview at the 2012 24th Annual Piper Jaffray Healthcare Conference
11/7/12	Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and Recent Corporate Developments
11/6/12	Sarepta Therapeutics to Present Company Overview at the 2012 Lazard Capital Markets 9th Annual Healthcare Conference
11/5/12	Sarepta Therapeutics Names Sandy Mahatme Senior Vice President, Chief Financial Officer and Ty Howton Senior Vice President, General Counsel
10/30/12	Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and Corporate Update Conference Call
10/12/12	Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 17th Annual International World Muscle Society

IR Menu